- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04698603
Clinical Study of GH001 in Depression
A Phase 1/2 Study of GH001 in Patients With Treatment-Resistant Depression
The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive symptoms, and its dose-related psychoactive effects in patients with Treatment-Resistant Depression (TRD).
The study is comprised of two open-label, single-arm study parts where Part A evaluates single doses of GH001 at two dose levels and Part B evaluates a specific individualized dosing regimen of GH001.
Study Overview
Status
Intervention / Treatment
Detailed Description
Phase 1 (Part A):
The primary objective of this study is to assess the safety and tolerability of single doses of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT) in patients with TRD.
The secondary objectives of the study are to assess the effects of single doses of GH001 on various measures of depression, and on dose-related psychoactive effects.
Phase 2 (Part B):
The primary objective of this study is to assess the effects of an individualized dosing regimen of GH001 on the severity of depression.
The secondary objectives of the study are to assess the safety and tolerability of an individualized dosing regimen of GH001 in patients with TRD and its effects on the severity of depression, other measures of depression, and on dose-related psychoactive effects.
Study design: Phase 1/2 study in two parts.
Intervention: In the Phase 1 (Part A), a single dose of GH001 will be administered per patient. Two different dose levels will be investigated with four patients at each dose level. In the Phase 2 (Part B), an individualized dosing regimen will be administered.
In both parts, GH001 will be administered via inhalation.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Maastricht, Netherlands
- Clinical Trial Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Has a body mass index (BMI) in the range of 18.5 and 35.0 kg/m2 (inclusive);
- Meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) or recurrent MDD, without psychotic features confirmed by the Mini-International Neuropsychiatric Interview (MINI);
- Treatment-Resistant Depression as evaluated by the Antidepressant Treatment History Form - Short Form (ATHF-SF);
- Has outpatient status at screening and enrolment visits;
Exclusion Criteria:
- Has a current or prior diagnosis of a psychiatric comorbidity that renders the patient unsuitable for the study according to a study psychiatrist or registered psychologist;
- Has received any investigational medication within the last 1 month;
- Has a current medically significant condition (e.g., severe infection) or has a history of a medically significant condition (e.g., medical history of seizure, uncontrolled hypertension, uncontrolled diabetes, severe cardiovascular disease, hepatic or renal failure, etc.) that renders the patient unsuitable for the study according to the medical supervisor's judgment;
- Takes any medication or other substance that renders the patient unsuitable for the study according to the medical supervisor's judgment;
- Has a clinically significant abnormality in physical examination, vital signs, ECG, or clinical laboratory parameters, which renders the patient unsuitable for the study according to the medical supervisor's judgment;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1 (Part A): GH001 dose A
|
GH001 administered via inhalation
Other Names:
|
Experimental: Phase 1 (Part A): GH001 dose B
|
GH001 administered via inhalation
Other Names:
|
Experimental: Phase 2 (Part B): GH001 Individualized Dosing Regimen
|
GH001 administered via inhalation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: The safety and tolerability of GH001 as a combined measure of outcomes 5 to 13.
Time Frame: up to 7 days
|
Phase 1: The primary endpoint is a binary variable (yes/no) reflecting a combined medical/clinical evaluation of the occurrence of Outcomes 5 to 13.
The endpoint will be considered met for any dose level or regimen if the Study Safety Group (SSG) - through a qualitative medical/clinical evaluation - considers that dose level or regimen sufficiently safe and tolerable for potential further clinical development in a subsequent study.
|
up to 7 days
|
Phase 2: The effects of GH001 on the severity of depression evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame: up to 7 days
|
Phase 2: The assessment is done with the Montgomery-Asberg Depression Rating Scale (MADRS), a diagnostic questionnaire with ten items for measuring the severity of depressive episodes in patients with mood disorders.
A higher MADRS score indicates more severe depression, and each item is scored from 0 to 6.
The overall score ranges from 0 to 60.
|
up to 7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: The effects of GH001 on the severity of depression evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame: up to 7 days
|
Phase 1: The assessment is done with the Montgomery-Asberg Depression Rating Scale (MADRS), a diagnostic questionnaire with ten items for measuring the severity of depressive episodes in patients with mood disorders.
A higher MADRS score indicates more severe depression, and each item is scored from 0 to 6.
The overall score ranges from 0 to 60.
|
up to 7 days
|
Phase 2: The safety and tolerability of GH001 as a combined measure of outcomes 5 to 13
Time Frame: up to 7 days
|
Phase 2: The secondary endpoint is a binary variable (yes/no) reflecting a combined medical/clinical evaluation of the occurrence of Outcomes 5 to 13.
The endpoint will be considered met for any dose level or regimen if the Study Safety Group (SSG) - through a qualitative medical/clinical evaluation - considers that dose level or regimen sufficiently safe and tolerable for potential further clinical development in a subsequent study.
|
up to 7 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Type and Frequency of Adverse Events
Time Frame: up to 7 days
|
Adverse events reported in the study and coded by MedDRA.
|
up to 7 days
|
Frequency of clinically significant changes from baseline in the safety laboratory analyses (biochemistry, hematology, urinalysis)
Time Frame: up to 7 days
|
Safety laboratory analyses are analyses of blood samples (biochemistry, hematology) and urine samples (urinalysis).
Changes are defined as any clinically significant change from baseline as determined by the medical supervisor at the site.
|
up to 7 days
|
Frequency of clinically significant changes from baseline in Vital Signs
Time Frame: up to 7 days
|
Vital signs include heart rate (beats per minute), blood pressure (mmHg), respiratory rate (breaths per minute), oxygen saturation (%), and temperature (degrees celsius).
Changes are defined as any clinically significant change from baseline as determined by the medical supervisor at the site.
|
up to 7 days
|
Frequency of clinically significant changes from baseline in Electrocardiogram (ECG) parameters
Time Frame: up to 3 hours after administration of GH001
|
Clinically significant changes in ECG include any significant change in rate or rhythm as determined by the medical supervisor at the site.
|
up to 3 hours after administration of GH001
|
Change from baseline in the Brief Psychiatric Rating Scale (BPRS)
Time Frame: up to 7 days
|
Change from baseline in the Brief Psychiatric Rating Scale (BPRS).
A scale to measure psychiatric symptoms.
Each symptom is rated 1-7 and a total of 18 symptoms are scored.
Combined score ranges from 18 to 126.
|
up to 7 days
|
Change from baseline in the Clinician Administered Dissociative States Scale (CADSS)
Time Frame: up to 7 days
|
Change from baseline in the Clinician Administered Dissociative States Scale (CADSS). The CADSS comprises 19 subjective items, ranging from 0 'not at all' to 4 'extremely. Summed together, these subscales form a total dissociative score. Combined score ranges from 0 to 76. |
up to 7 days
|
Change from baseline in the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: up to 7 days
|
Change from baseline in the Columbia-Suicide Severity Rating Scale (C-SSRS).
A detailed questionnaire assessing both suicidal behaviour and suicidal ideation.
No combined score is created.
|
up to 7 days
|
Change from baseline in the Psychomotor Vigilance Test (PVT)
Time Frame: up to 7 days
|
Change from baseline in the Psychomotor Vigilance Test (PVT).
A computerized test assessing the reaction time in response to a visual stimulus.
Outcome measures are Response Time and the number of attentional lapses (Response Time ≥ 500 msec).
|
up to 7 days
|
Change from baseline in Digit Symbol Substitution Test (DSST)
Time Frame: up to 7 days
|
Change from baseline in the Digit Symbol Substitution Test (DSST).
A computerized test with the task is to match digits with symbols from encoding list.
The number of digits correctly encoded within 3 minutes is the performance measure.
|
up to 7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: GH Research Clinical Team, GH Research Ireland Limited
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Depressive Disorder, Treatment-Resistant
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Receptor Agonists
- Serotonin Antagonists
- Hallucinogens
- N,N-Dimethyltryptamine
Other Study ID Numbers
- GH001-TRD-102
- 2018-004208-20 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Lawson Health Research InstituteTerminated
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on 5 Methoxy N,N Dimethyltryptamine
-
GH Research Ireland LimitedCompleted
-
GH Research Ireland LimitedRecruitingPostpartum Depression | Postnatal DepressionUnited Kingdom, Netherlands
-
GH Research Ireland LimitedRecruitingTreatment-resistant DepressionIreland, Czechia
-
GH Research Ireland LimitedRecruiting
-
GH Research Ireland LimitedCompleted
-
GH Research Ireland LimitedCompleted
-
University Hospital, Basel, SwitzerlandNot yet recruiting
-
University Hospital, Basel, SwitzerlandRecruiting
-
Usona InstituteCompletedPharmacokinetics | Tolerability | SafetyUnited States
-
Small Pharma LtdCompleted